Juliette Thariat

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

David Thomson, David A. Palma, Matthias Gückenberger et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 209 citations · Full text

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

Thibaud Valentin, Axel Le Cesne, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2016 · 187 citations

Neuro-oncology, Surgical Oncology, Tumoral Pathology +7

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

Éric Lartigau, Emmanuelle Tresch, Juliette Thariat et al. · Radiotherapy and Oncology · 2013 · 179 citations

Concomitant Stereotactic Reirradiation, Neck Cancer, Radiation Therapy +13

A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)

M. Frikha, A. Aupérin, Yungan Tao et al. · Annals of Oncology · 2017 · 169 citations

Medicine, Metronomic Therapy, Pathology +8